- Home
- TXMD vs ASBP Comparison
TXMD vs ASBP Comparison
Compare TXMD & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- ASBP
- Stock Information
- Founded
- TXMD 2008
- ASBP 2021
- Country
- TXMD United States
- ASBP United States
- Employees
- TXMD N/A
- ASBP N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- ASBP Health Care
- Exchange
- TXMD Nasdaq
- ASBP Nasdaq
- Market Cap
- TXMD 13.5M
- ASBP 14.5M
- IPO Year
- TXMD N/A
- ASBP N/A
- Fundamental
- Price
- TXMD $1.14
- ASBP $0.36
- Analyst Decision
- TXMD
- ASBP
- Analyst Count
- TXMD 0
- ASBP 0
- Target Price
- TXMD N/A
- ASBP N/A
- AVG Volume (30 Days)
- TXMD 30.4K
- ASBP 7.7M
- Earning Date
- TXMD 07-30-2025
- ASBP 08-24-2025
- Dividend Yield
- TXMD N/A
- ASBP N/A
- EPS Growth
- TXMD N/A
- ASBP N/A
- EPS
- TXMD N/A
- ASBP N/A
- Revenue
- TXMD $1,841,000.00
- ASBP N/A
- Revenue This Year
- TXMD $427.09
- ASBP N/A
- Revenue Next Year
- TXMD N/A
- ASBP N/A
- P/E Ratio
- TXMD N/A
- ASBP N/A
- Revenue Growth
- TXMD 53.55
- ASBP N/A
- 52 Week Low
- TXMD $0.70
- ASBP $0.22
- 52 Week High
- TXMD $2.44
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- TXMD 43.84
- ASBP N/A
- Support Level
- TXMD $1.07
- ASBP N/A
- Resistance Level
- TXMD $1.24
- ASBP N/A
- Average True Range (ATR)
- TXMD 0.08
- ASBP 0.00
- MACD
- TXMD 0.00
- ASBP 0.00
- Stochastic Oscillator
- TXMD 59.62
- ASBP 0.00
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.